Skip to Content

Microbix Biosystems Inc MBXBF

Morningstar Rating
$0.24 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MBXBF is trading at a 673% premium.
Price
$0.24
Fair Value
$4.35
Uncertainty
Very High
1-Star Price
$2.70
5-Star Price
$5.66
Economic Moat
Mvpkk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MBXBF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.24
Day Range
$0.240.24
52-Week Range
$0.170.33
Bid/Ask
$0.20 / $0.29
Market Cap
$33.25 Mil
Volume/Avg
6,900 / 12,394

Key Statistics

Price/Earnings (Normalized)
27.04
Price/Sales
1.89
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
1.80%

Company Profile

Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
100

Valuation

Metric
MBXBF
Price/Earnings (Normalized)
27.04
Price/Book Value
1.76
Price/Sales
1.89
Price/Cash Flow
12.64
Price/Earnings
MBXBF

Financial Strength

Metric
MBXBF
Quick Ratio
4.66
Current Ratio
6.64
Interest Coverage
4.92
Quick Ratio
MBXBF

Profitability

Metric
MBXBF
Return on Assets (Normalized)
4.91%
Return on Equity (Normalized)
7.64%
Return on Invested Capital (Normalized)
6.73%
Return on Assets
MBXBF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
HgqxrytfXrp$626.5 Bil
Vertex Pharmaceuticals Inc
VRTX
PqnhdsfzQvpptz$122.2 Bil
Regeneron Pharmaceuticals Inc
REGN
VbqxhcwsVklzm$115.2 Bil
Moderna Inc
MRNA
KlpzmysXgzzr$52.8 Bil
argenx SE ADR
ARGX
MvrztrhzJrtn$23.0 Bil
BioNTech SE ADR
BNTX
KgystllcXmry$21.3 Bil
Alnylam Pharmaceuticals Inc
ALNY
RrxsvccyFfnlxhz$19.9 Bil
Biomarin Pharmaceutical Inc
BMRN
MjmfmbfWqqcflf$16.1 Bil
United Therapeutics Corp
UTHR
VllvqrnKzmf$13.2 Bil
Incyte Corp
INCY
YgclnvjqtBqfsd$12.4 Bil

Sponsor Center